Zhou Xiaowei, Li Ying, Zhang Mingyu, Hao Junjie, Gu Qiong, Liu Haiyang, Chen Wei, Shi Yafei, Dong Bin, Zhang Yuanyuan, Li Chunyu, Li Guohui
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Evid Based Complement Alternat Med. 2019 Sep 22;2019:7282681. doi: 10.1155/2019/7282681. eCollection 2019.
Nowadays, an increasing number of patients are seriously affected by lung cancer. Si Jun Zi Tang (SJZ), a four-herb Chinese medicine formula first described approximately one thousand years ago, is often prescribed for cancer patients as a complementary therapy. But the research on the effective materials for treating cancer using SJZ was rarely reported. To solve this problem, we evaluate the inhibitory effect of 10 samples of SJZ from different origins on PC9 cells. Ultraperformance liquid chromatography (UPLC) and hierarchical cluster analysis (HCA) along with canonical correlation analysis (CCA) and bioactivity validation were used to investigate the underlying correlation between the chemical ingredients and the antiproliferative effect of SJZ on PC9 cells. The evaluation indicated that 10 batches of SJZ could inhibit proliferation of PC9 cells and there was a notable difference in pharmacological activity between the different SJZ samples. The results of CCA and multivariate statistical analysis indicated that ginsenoside Ro and ginsenoside Rg1 might be active constituents of the antiproliferative effect as determined by spectrum-effect relationships. The results showed that bioassay and spectrum-effect relationships are suitable to associate sample quality with the active ingredient associated with clinical efficacy. And our finding would provide foundation and further understanding of the quality evaluation of traditional Chinese medicine decoction.
如今，越来越多的患者受到肺癌的严重影响。四君子汤（SJZ）是一种大约一千年前首次记载的由四味中药组成的方剂，常作为辅助疗法开给癌症患者。但关于使用四君子汤治疗癌症的有效物质的研究鲜有报道。为解决这一问题，我们评估了来自不同产地的10个四君子汤样品对PC9细胞的抑制作用。采用超高效液相色谱（UPLC）、层次聚类分析（HCA）以及典型相关分析（CCA）和生物活性验证来研究化学成分与四君子汤对PC9细胞抗增殖作用之间的潜在相关性。评估表明，10批四君子汤均可抑制PC9细胞的增殖，不同的四君子汤样品之间药理活性存在显著差异。CCA和多变量统计分析结果表明，根据谱效关系，人参皂苷Ro和人参皂苷Rg1可能是抗增殖作用的活性成分。结果表明，生物测定和谱效关系适用于将样品质量与临床疗效相关的活性成分联系起来。我们的发现将为中药汤剂质量评价提供基础并加深理解。
